MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
Withdrawn
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is evaluate the safety and tolerability of MPH966, a neutrophil
elastase inhibitor, and its ability to prevent graft-versus-host disease after hematopoietic
stem cell transplant.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Nelson Chao
Collaborators:
Mereo BioPharma National Center for Advancing Translational Science (NCATS)